Pipelinepharma Marketplace Records Quadruple Growth Over a Single Year
The leading European pharmaceutical marketplace now hosts more than 85 000 CTD dossiers for finished dosage formulation products. Compared to 19 600 products at the start of 2021, the product offering has increased fourfold over a single year. As a response to increasing demand, Pipelinepharma will introduce biosimilar drugs into a separate category. New finished dosage form categories for medical devices and nutraceuticals will also be launched in the coming months. - April 01, 2022
Cooperative Buying to Help Launch New Medicines in Small Markets
Large manufacturer minimum order quantities put specialist medicines out of reach of buyers in smaller markets. By grouping pharmaceutical orders from different buyers into a single collective bulk order, Pipelinepharma will help buyers to reach the minimum order quota. The initiative further builds upon Pipelinepharma’s mission to provide better access to medicines for patients all around the world. - February 17, 2022
Pharmaceutical Companies Shift to Near-Shore Medicines Sourcing as Supply Chain Risks Intensify
With global supply chains under stress due to COVID-19 pandemic, European pharmaceutical companies and distributors are increasingly looking for alternative supply channels inside the EU block. - December 16, 2021
Pipelinepharma Closes €1.3M Seed Round to Shift Pharmaceutical Dealmaking Online
The European B2B pharmaceutical marketplace closed a venture seed round led by Practica Capital. Iron Wolf Capital, Pandos and a group of angel investors also participated in the funding round. - October 09, 2021